801
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluating lurasidone as a treatment option for bipolar disorder

, &
Pages 253-260 | Received 31 Jul 2019, Accepted 18 Nov 2019, Published online: 19 Jan 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ahmad Sleem & Rif S. El-Mallakh. (2021) Advances in the psychopharmacotherapy of bipolar disorder type I. Expert Opinion on Pharmacotherapy 22:10, pages 1267-1290.
Read now

Articles from other publishers (6)

Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo & Marco Andrea Riva. (2024) Transcriptomic analyses of rats exposed to chronic mild stress: Modulation by chronic treatment with the antipsychotic drug lurasidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 129, pages 110885.
Crossref
Qingqing Li, Jing Wang, Zheng-lu Wang, Yuxin Shen, Qi Zhou, Ya-nan Liu, Guo-xin Hu, Jian-ping Cai & Ren-ai Xu. (2023) The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone. Biomedicine & Pharmacotherapy 168, pages 115833.
Crossref
Philip B. Mitchell. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry 1 31 .
Siu Wa Tang, Wayne H. Tang & Brian E. Leonard. (2021) Treatment-induced mood switching in affective disorders. Acta Neuropsychiatrica 34:2, pages 55-68.
Crossref
Khadijeh Moulaei, Kambiz Bahaadinbeigy & Shahrzad Mazhari. (2022) Designing the minimum data set of bipolar disorder: A basis for introducing the effective factors in managing, controlling, and monitoring the bipolar disorder. Journal of Education and Health Promotion 11:1, pages 147.
Crossref
Rif S. El-Mallakh & Ziad Ali. (2021) Extra-synaptic modulation of GABAA and efficacy in bipolar disorder. Medical Hypotheses 147, pages 110501.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.